Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The decrease in breast-cancer incidence in 2003 in the United States.

Peter M Ravdin1, Kathleen A Cronin, Nadia Howlader

  • 1Department of Biostatistics, M.D. Anderson Cancer Center, Houston, USA.

The New England Journal of Medicine
|April 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

A Roadmap to Transform Lung Cancer Outcomes: Priorities in Biology, Therapeutic Innovation, Early Detection, Prevention, and Interception.

Cancer discovery·2026
Same author

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2<sup>+</sup> breast cancer: TBCRC049 phase 2 study results.

Nature cancer·2026
Same author

Statistical innovations in clinical trial design with a focus on drug combinations, factorials, and other multiple therapy issues.

The journal of prevention of Alzheimer's disease·2025
Same author

Extracellular vesicle and particle-based blood test for ovarian cancer screening of average risk population: a promising nested case control study using preclinical samples.

Gynecologic oncology·2025

Breast cancer incidence decreased significantly in US women in 2003, particularly in older women using hormone replacement therapy. This trend stabilized by 2004, suggesting a link to reduced hormone therapy use.

Area of Science:

  • Oncology
  • Epidemiology
  • Public Health

Background:

  • The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program collects data on cancer incidence and survival in the United States.
  • Hormone replacement therapy (HRT) use among postmenopausal women has been a subject of public health interest due to potential health implications.

Observation:

  • A sharp 6.7% decline in age-adjusted breast cancer incidence was observed in 2003 compared to 2002.
  • Data from 2004 indicated a leveling off of this decrease.
  • Regression analysis pinpointed the decline's onset in mid-2002 and stabilization by mid-2003.

Findings:

  • Overall age-adjusted breast cancer incidence decreased by 8.6% between 2001 and 2004.
  • The reduction was primarily observed in women aged 50 and older.

Related Experiment Videos

  • Estrogen-receptor-positive breast cancers showed a more pronounced decrease than estrogen-receptor-negative cancers.

    • Implications:

    • The observed decrease in breast cancer incidence appears temporally associated with the Women's Health Initiative findings and subsequent reduction in HRT use.
    • While other factors are not excluded, the decline in HRT use is the most likely contributor to the observed incidence changes.
    • These findings highlight the impact of therapeutic interventions on population-level cancer incidence rates.